Outlier in fixed dose combination [Outliers]

posted by yoyo87 – Egypt, 2022-07-21 14:01 (323 d 02:09 ago) – Posting: # 23154
Views: 497

Dears

In a BE study of bilayer fixed combination product, one is immediate release and other is sustained, one volunteer in one phase shows no concentrations for the immediate release product (test product) :confused:, while the other sustained active ingredient shows normal concentration profile, all other phases in the volunteer also show regular profile for both actives, no evidence for emesis or any adverse event occurred, what is the probability of this case, could this volunteer be outlier, or its related to the formulation and production? what the suggested solution for this case, that could be accepted by authorities?

Thanks

Complete thread:

UA Flag
Activity
 Admin contact
22,627 posts in 4,743 threads, 1,613 registered users;
22 visitors (0 registered, 22 guests [including 13 identified bots]).
Forum time: 16:11 CEST (Europe/Vienna)

Facts are meaningless. You could use facts to prove
anything that’s even remotely true!    Homer Simpson

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5